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Background: Myelinated retinal nerve fibres (MRNFs) are congenital anomalies of the fundus that 
occur in about 1% of the population. Clinically, they appear as grey or white well-separated patches 
with feathery borders along the retinal nerve fibre layer. MRNF has been reported to occur in associa-
tion with some ocular parameters as well as stroke. However, most cases of MRNF occur in isolation 
and are asymptomatic. 
Purpose: To determine the prevalence, ocular and systemic associations of MRNF in Tromsø. 
Methods: The present study included 7396 participants aged 40–84 years from the Tromsø Eye Study, 
a sub-study of the population-based Tromsø Study in Norway. Data on ocular and systemic parameters 
were collected from self-report questionnaires, clinical examinations, and laboratory measurements. 
Retinal images from both eyes were assessed for the presence of MRNF. Logistic regression models 
were used to assess the association between MRNF and ocular and systemic parameters.  
Results: Readable fundus photographs of at least one eye were available in 7396 (88.0%) of 8346 
participants of the Tromsø eye study (TES). The study cohort included 3979 (55.8%) females and 3417 
(46.2%) males. The mean age in the whole study cohort was 62.9 ± 10.4 years with 62.8 ± 10.4 and 
63.1 ± 10.4 years in females and males respectively. The prevalence of MRNF in the study sample was 
1.1%. In a multivariable logistic regression analysis, MRNF was associated with male sex (OR, 1.785; 
95% CI, 1.138–2.799; P, 0.012) and glycosylated haemoglobin (HbA1c) (OR, 0.559; 95%CL, 0.316 – 
0.989; P, 0.046). MRNF was not associated with age, systemic conditions or ocular parameters such 
as visual acuity, refractive error, or intraocular pressure. 
Conclusion: This population-based study is the first to provide data on the prevalence of MRNF in the 
Nordic population. It is also the first study to report an association between MRNF and HbA1c, alt-
hough this may be a chance finding and must be explored further. This study tends to affirm the general 
perception that MRNF is without serious clinical implications, however, this must also be investigated 
further in future studies.  
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1.1.1 The Eye as a window into the brain 
Over the years, the concept that 'the eye is a window into the brain', has become increasingly popular and 
relevant. During normal prenatal development, the retina and the optic nerve emerge from a relatively 
small part of the central nervous system (CNS) called diencephalon and, therefore, are considered part of 
the CNS (London et al., 2013). The retina comprises of layers of specific neurons that are interconnected 
through synapses. When light enters the eye, it is captured by the photoreceptor cells in the retina. These 
photoreceptor cells then trigger a surge of neuronal signals that travel to the retinal ganglion cells (RGCs). 
The axons of the RGCs extend to the lateral geniculate nucleus in the thalamus and the superior colliculus 
in the midbrain, from where visual impulse is further transmitted to the higher visual centres that enable 
us to see a picture of our world (London et al., 2013). 
The connection between the eye and the brain is made possible through the visual pathway. The latter 
consists of, in addition to the retina and optic nerve, the optic chiasma, optic tract, lateral geniculate nu-
cleus, optic radiations, and visual cortex. As an extension of the CNS, the retina shows characteristics akin 
to the brain and spinal cord in terms of its anatomical features, functionality, inflammatory response, and 
immunology (London et al., 2013). There is a close similarity between both the retinal and cerebral micro 
and macro-vasculatures and, these vascular networks also share identical vascular regulatory processes 
(Patton et al., 2005). Hence, changes in the retinal vasculature may lead to similar changes in the vascular 
networks of the brain. The similarity between the blood-brain-barrier (BBB) and blood-retinal barrier 
(BRB) and “immune privilege” involved in preventing harmful immune system reactions in both the CNS 
and the eye, also gives credence to their shared origin (Allegri, Rissotto, Herbort, & Murialdo, 2011).  
Given the similarities and connections between the eye and the brain, lessons from eye research could be 
applied to the brain and vice versa (London et al., 2013). Figure 1 represents the connection between the 






Figure 1: The Eye as an extension of the CNS. 
 
a) The layers of the retina consist of diverse types of neuron including retinal ganglion cells, which share a similar structure 
with other CNS neurons; 
b) The axons of these cells are myelinated by oligodendrocytes just behind the globe, giving rise to the optic nerve, which 
stretches to the Lateral Geniculate Nucleus (LGN) and Superior Colliculus (SC) of the brain;  
c) Similar to CNS neurons, an insult to the optic nerve creates an environment that both threatens the survival of neurons 
as well as hinders the regeneration of injured axons;  
d) Like the CNS, the eye shares a special connection with the immune system that involves both the inner blood-retinal 
barrier, the retinal counterpart of the CNS’s blood-brain barrier and  
e) The extremely important immunoregulatory molecules.  
Note: Adapted from (London et al., 2013).  





1.1.2 Ocular manifestations of CNS disorders 
Besides having common embryogenic developmental pathway, the posterior segment of the eye and the 
CNS also have shared vascular pathogenesis (Dhillon & Dhillon, 2008). Several diseases of the CNS have 
been shown to manifest in the retina (Allegri et al., 2011; London et al., 2013). For instance, previous 
prospective studies have suggested that abnormal retinal signs such as narrowing of arterioles, arteriove-
nous nicking and retinal haemorrhages could potentially predict the risk of clinical stroke events (Cheung 
et al., 2010), ischemic brain changes (T. Y. Wong et al., 2002), as well as stroke mortality (Tien Yin Wong 
et al., 2001). More so, retinal arteriovenous nicking and hypertensive ocular fundus abnormalities have 
been reported in association with increased risk of incident brain infarction (Tien Yin Wong et al., 2001; 
T. Y. Wong et al., 2002). In addition, studies conducted with animal models have linked cerebral infarction 
to conditions like reactive gliosis, thinning of the retinal nerve fibre layer, as well as optic neuropathy 
(Kalesnykas, Tuulos, Uusitalo, & Jolkkonen, 2008).  
Compared to healthy controls, patients with Alzheimer disease have been reported to show certain abnor-
mal retinal signs such as narrow retinal veins (Berisha, Feke, Trempe, McMeel, & Schepens, 2007), optic 
nerve fibre loss (Danesh-Meyer, Birch, Ku, Carroll, & Gamble, 2006), thinning of retinal nerve fibre 
layers (RNFLs) (Parisi et al., 2001), as well as decreased retinal blood flow and extensive retinal ganglion 
cell loss (Berisha et al., 2007; Blanks, Torigoe, Hinton, & Blanks, 1996). Similarly, substantial retinal 
involvements have been observed in patients with Parkinson’s disorder (Guo, Normando, Shah, De Groef, 
& Cordeiro, 2018; Inzelberg, Ramirez, Nisipeanu, & Ophir, 2004; Moschos et al., 2011), Lymphoma 
(Buggage, Chan, & Nussenblatt, 2001), and Multiple sclerosis (Jennifer B. Fisher et al., 2006).  
Importantly, many changes in the eye have been identified and described through ophthalmological eval-
uation in patients with CNS diseases (London et al., 2013). Even though some ocular manifestations are 
not specific to one particular disease, their presence, however, emphasizes the strong link the eye shares 





Figure 2: Ocular manifestations of CNS disorders.   
a) Retinal Nerve Fiber Layer thinning, optic nerve degeneration, reactive cell gliosis and abnormal retinal microvas-
culature are some of the ocular changes seen in stroke conditions; 
b) Cupping of the optic nerve, RGC loss, retinal atrophy and decreased visual acuity are commonly observed in the eye 
of patients with Multiple Sclerosis; 
c) Ocular changes seen in Parkinson’s Disorder include retinal dopamine deficiency, swollen neurons, RNFL thinning, 
electrophysiological abnormalities as well as deterioration of visual acuity; 
d) In patients with Alzheimer Disease, retinal changes manifest as RCG loss, RNFL thinning, and abnormal accumula-
tion of Aβ and p-tau, reminiscent of the disease phenotype in the brain.  
Note: Adapted from (London, Benhar, & Schwartz, 2013). 
Abbreviations: Aβ, amyloid-β; AD, Alzheimer disease; MS, multiple sclerosis; PD, Parkinson disease; p-tau, phosphorylated 




1.1.3 Retinal Nerve Fiber Layer and the process of Myelination 
The retinal nerve fibre layer (RNFL) is one of the ten layers of the human retina. It is situated anterior to 
the ganglion cell layer and posterior to the inner limiting membrane, and shelters the muller cells that 
cover the retinal vascular plexuses and nerve fibres. The RNFL comprises of the ganglion cell axons, 
neuroglia cells, and astrocytes. The ganglion cell axons run parallel to the surface of the retina, collect in 
a bundle at the optic disc and emerge from the back of the eye to form the optic nerve. The Neuroglia cells 
form myelin and provide support and protection for neurons. A dense collection of astrocytes at the lamina 
cribosa provides a barrier preventing oligodendrocytes from migrating to the retina. Within the retina, the 
nerve fibres are typically not myelinated and exit the eye through the lamina cribosa as the optic nerve. 
Upon leaving the eye, the axons of the ganglion cells become myelinated (Forrester, Dick, McMenamin, 
Roberts, & Pearlman, 2015). In a healthy human eye, the thickness of RNFL ranges from about 10 μm 
(around the fovea) to about 400 μm (margin of the optic disc) (Varma, Skaf, & Barron, 1996). However, 
the thickness of RNFL has been reported to decrease with age (Varma et al., 1996), and in conditions such 
as glaucoma (Sugita et al., 2015), Retinitis pigmentosa (Walia, Fishman, Edward, & Lindeman, 2007), 
Alzheimer disease (Parisi et al., 2001), and multiple sclerosis (Jennifer B Fisher et al., 2006).  
Myelination is a process in which axons become ensheathed by highly specialized myelin. It is the final 
stage involved in the development of the brain. Through this process, myelinated axons are capacitated to 
transmit electrical impulses at a faster speed than unmyelinated ones, thereby facilitating neuronal activity 
and communication. Different regions of the brain show different timings of myelination (Tierney & 
Nelson III, 2009, p. 9). For instance, myelination begins at the sensory (e.g. visual system) and motor 
regions during the third trimester and continues until about the preschool age. By contrast, myelination is 
not complete until adolescence or early adulthood in areas involved in higher cognitive functions. As a 
developmental anomaly, myelination occasionally spreads to the anterior part of the lamina cribosa along 
the nerve fibres of the optic disc and the retina. The myelination of the retinal may be continuous with or 
completely detached from the optic disc (Straatsma, Foos, Heckenlively, & Taylor, 1981). 
1.1.4 Myelinated Retinal Nerve Fibers 
Myelinated (or medullated) retinal nerve fibres (MRNFs) are non-inflammatory retinal lesions that occur 




fibre layer is transparent and unmyelinated, thus, allowing retinal blood vessels to be easily visualized. 
But in MRNF, the underlying retinal blood vessels and disc are obscured. MRNF lesions are diagnosable 
clinically, and are recognized on fundus examination as grey or white well-separated patches with feathery 
borders along the retinal nerve fibre layer (Osaguona & Uhumwangho, 2014). They have been reported 
to occasionally occur in other parts of the retina as well as in the fovea (Osaguona & Uhumwangho, 2014). 
In the mid-eighteenth century, a German pathologist named Rudolf Virchow first described the pathologic 
features of MRNF as follows: 
“Retina was white, very thick and wrinkled. Macula was normal and near the optic disc, though more 
deeply situated, were thick, opaque, chalk-white spots, which spread around the disc in the shape of a 
star, so that when I wanted to draw the line between the disc and macula on each side of the two had the 
same divergence. In the other eye, I found, without much surprise, in the same place, the ring around the 
disc with a width of 2–2, 5 mm, regressing towards the outside” (Grzybowski & Winiarczyk, 2015). 




Clinically, most cases of MRNF represent benign clinical findings (Rao, Turkoglu, Say, & Shields, 2019). 
Some patients with MRNF may experience no troubling symptoms; however, visual functions have been 
reported to be significantly impacted especially in patients with axial myopia, amblyopia, and strabismus 
in the affected eye (Tarabishy, Alexandrou, & Traboulsi, 2007). MRNFs are mostly unilateral, although 
bilateral cases of the lesions have also been observed in some of the affected patients (Straatsma, 
Heckenlively, Foos, & Shahinian, 1979). 
1.1.5 Epidemiology and Pathogenesis of MRNF 
Previous studies have reported varying results on the prevalence of MRNF. In a study of 3,968 autopsy 
cases, Straatsma and colleagues found MRNF to be present in 0.98% of the subjects and in 0.54% of eyes 
examined, with bilateral involvement in about 8% of the study sample (Straatsma et al., 1979). A popula-
tion-based study in India found MRNF to be present in approximately 1% of the Indian adults examined 
(Nangia et al., 2014). The Beijing Eye Study reported a 0.7% prevalence of MRNF among elderly Chinese 
in Northern China (You, Xu, & Jonas, 2007). The lesions have also been reported in 0.57% of 5789 Jap-
anese (Kodama, Hayasaka, & Setogawa, 1990), as well as in 0.4% of 12,960 Caucasian cohorts in Western 





Germany (Elbaz et al., 2016). While some studies have reported male predominance (Tarabishy et al., 
2007); Straatsma and colleagues, however, reported no statistically significant gender-difference in 
MRNF prevalence (Straatsma et al., 1979). Although familiar cases of MRNF rarely occur, a few have 
been reported to occur both in isolation and in combination with ocular and systemic abnormalities 
(Ramkumar, Verma, Ferreyra, & Robbins, 2018).  
The pathogenesis of MRNF has not been sufficiently described, however, Oligodendrocytes have been 
implicated (Elbaz et al., 2016). Oligodendrocytes are the major supporting cells of the CNS responsible 
for medullating axons in order to accelerate the conduction of electric signals along the nerves (Elbaz et 
al., 2016). Before birth, the process of optic nerve myelination starts at the lateral geniculate body, and 
continues anteriorly towards the eye to terminate at the lamina cribosa – widely regarded as a major im-
pediment against myelination (M. S. Lee & Gonzalez, 1998; Tarabishy et al., 2007).  Thus, under a normal 
circumstance, the process of myelination of the optic nerve stops at the lamina cribosa and the retinal 
nerve fibres remain unmyelinated.  
Nevertheless, in MRNF, the retinal nerve fibres are also ensheathed with myelin. In a histological study 
of MRNF samples, Straatsma and colleagues found oligodendrocyte-like cells in the retina, while at the 
same time reporting an intact-looking lamina cribosa (Straatsma et al., 1981). There could be two possible 
explanations for this: it is either the progenitors of oligodendrocytes moved to the retina before the barrier 
function of lamina cribosa was fully developed, or they moved at a time when the functional integrity of 
lamina cribosa was temporarily compromised (Tarabishy et al., 2007). The myelination of the retinal nerve 
fibre has also been speculated to result from medullated glial cells of the immune system that were acti-
vated to the retina in the uterus (Tarabishy et al., 2007). Some studies have suggested that the development 
of the acquired form of MRNF could be as a result of possible optic nerve injury caused by optic nerve 
head drusen or increased intracranial pressure (Prakalapakorn & Buckley, 2012). Besides, there is a re-
ported case of MRNF resulting from an optic pathway glioma, which could have led to the disruption of 
the lamina cribosa (Eneh, Schweitzer, & Sharma, 2010).  
MRNFs are usually regarded as congenital and stable lesions, but a few cases of acquired and progressive 
lesions in both childhood and adulthood or after surgical procedures like optic nerve decompression have 




Gilman, Warner, & Katz, 2013). The lessions have also been reported to partially or totally regress in 
conditions such as multiple sclerosis (Sharpe & Sanders, 1975), glaucoma (Sowka & Nadeau, 2013), and 
post intraocular surgery (Williams & Fekrat, 2006). Furthermore, MRNF has been reported to occur in 
association with oculo-visual parameters such as visual field defects, myopia, amblyopia, and strabismus 
(M. S. Lee & Gonzalez, 1998), as well as systemic conditions like the Gorlin syndrome (De Jong et al., 
1985). 
Although the associations between MRNF and systemic parameters have not been fully investigated, how-
ever, the Gutenberg Health Study reported a positive association between MRNF and history of stroke in 
a Caucasian cohort in Western Germany (Elbaz et al., 2016). To the best of our knowledge, there is cur-
rently no published study describing the prevalence and associations of MRNF in the Nordic population. 
1.2 Statement of Problem 
As previously stated, the eye and in particular the retina is considered a window into the brain, and several 
studies have shown associations between retinal markers and systemic diseases (London et al., 2013). 
Although one previous study has reported an association between MRNF and a history of stroke (Elbaz et 
al., 2016), the clinical significance of MRNF is still unclear. The prevalence of MRNF has been reported 
in some regions, but to our current knowledge, no data exist from the Nordic populations. It is therefore 
important to investigate the prevalence of MRNF and its associations with ocular and systemic parameters 
with special focus on cardiovascular diseases and stroke. This study also seeks to yield data to a sparse 
data base on MRNF.   
1.2.1 Objectives of the Study 
The objectives of the present study included: 
 To determine the prevalence of MRNF in the Tromsø population. 
 To explore the relationship between MRNF and Sex and Age. 
 To identify ocular and visual parameters associated with MRNF. 
 To investigate systemic parameters associated with MRNF with special focus on cardiovascular 




1.2.2 Significance of the study 
The human eye provides a non-invasive means of detecting many systemic conditions (London et al., 
2013), therefore data from this present study would be utilized to clarify the clinical impact of random 
detection of MRNF in clinical routines. Generally, the awareness about MRNF and its potential associa-





2 Materials and Methods 
2.1 The Tromsø Study 
The Tromsø Study is a population-based prospective study in the municipality of Tromsø, Norway 
(Eggen, Mathiesen, Wilsgaard, Jacobsen, & Njølstad, 2013; Jacobsen, Eggen, Mathiesen, Wilsgaard, & 
Njølstad, 2012). The study design includes repeated population health surveys to which total birth cohorts 
and random samples are invited. The study started as a cardiovascular study of 6595 men in 1974 and was 
later expanded to include many other chronic diseases (Eggen et al., 2013). Women were included from 
the second survey in 1979/80, and new surveys subsequently took place in 1986/87, 1994/95, 2001, 
2007/08 and 2015/16. At each screening survey, a standard set of data was collected for all participants. 
Information was covered by questionnaires, measurements of blood pressure, height, weight, and blood 
analyses, amongst them serum lipids. Since the inception of the study, a total of 45473 subjects have 
participated in at least one of the seven surveys, while 18510 have participated on three or more occasions. 
To be eligible for the Tromsø Study, participants must be residents in the municipality of Tromsø based 
on the official population registry. The large number of variables collected in these surveys are described 
in more details on http://tromsoundersokelsen.uit.no/tromso/. Blood samples from each survey and DNA 
samples from the third survey and thereafter are securely stored in a bio-bank.  
2.1.1 Tromsø 6 & 7 Surveys 
The sixth (2007–2008) and the seventh (2015-2016) surveys comprised of two separate visits each. All 
participants were invited to a first visit where they filled a questionnaire and underwent physical exami-
nations that involved measurement of blood pressure, height, weight, and waist-to-hip ratio. Other tests 
conducted include blood sampling, bone mineral density and pain threshold tests. In each of the surveys, 
a large subgroup was invited to a second visit a few weeks after the first visit, where special investigations 
were performed. Eye examination was one of the special investigations conducted during the second visits 
of both Tromsø 6 and Tromsø 7 surveys and, thus, laid the foundation for the Tromsø Eye Studies 1 and 
2, respectively. In addition to the eye examination, each of these second visits included a second question-
naire, blood sampling, cognitive tests, ultrasound of the carotid artery, 12-lead electrocardiogram, echo-




2.1.2 Study Sample 
The sample for this present study is based on data from Tromsø Eye Study 2, which is a sub-study of the 
Tromsø 7 survey and a follow-up of the Tromsø Eye study 1 (TES 1). All inhabitants in the municipality 
of Tromsø aged 40 and older were invited to the first visit of Tromsø 7 survey (n=32591) and of those, 
21083 (64.7%) participated. A predefined random selection of 20% aged 40-59 years and 50% aged 60-
85 years (n=10150) supplemented with those who participated in the Tromsø Eye Study 1, but not included 
in the random selection (n=3154) were invited to the second visit of Tromsø 7, where Tromsø Eye Study 
2 was conducted. Participation in the first visit of Tromsø 7 survey was a prerequisite to be invited to the 
second visit. In total, 13304 subjects aged 40 years and above were invited to participate in the Tromsø 
Eye Study 2. Of those invited, 8346 (63%) subjects attended. However, retinal photographs were not 
available for 950 participants due to lack of consent or technical and logistic reasons, leaving a total of 






Figure 4: Flow diagram of the study sample. The Tromsø Eye study, 2015-16. 
Invited to first visit Tromsø 7, n =32591 
All inhabitants of Tromsø municipality aged 
40 and older 
Attended first visit Tromsø 7, n=21083 
Did not attend first 
visit Tromsø 7, n = 
11508 
Invited to second visit of Tromsø 7/ Tromsø 
Eye study 2, n= 13304: 
Participated in first visit Tromsø 7 
20% random sample aged 40-59 
50% random sample aged 60-85 
If not included above but participated in TES 1 
 
Did not attend second visit of 
Tromsø 7/ Tromsø Eye study 
2, n= 4958 
Attended second visit of Tromsø 7/ Tromsø 
Eye 2, n= 8346 (63% of invitees) 
Participants with valid retinal photos & in-
cluded in this study. n = 7396 (88.6% of at-
tendees) 
Did not have valid retinal 
photos, n = 950 




2.1.3 Eye Examinations 
In addition to the information gathered through questionnaires and a standardized medical examination, 
all the subjects included in this study underwent detailed eye examinations that included comprehensive 
ocular history. Auto-refraction and visual acuity (VA) assessments were performed with Nidek ARK 560a 
autorefractor (Nidek CO., LTD. Japan). Visual acuity was categorized into best eye and worst eye acuities. 
Visual impairment was classified based on the International Classification of Disease 11th edition (World 
Health Organization, 2018). Briefly, visual impairment was defined as no impairment (distant VA ≤ Log 
MAR 0.3), mild (worse than log MAR 0.3), moderate (worse than Log MAR 0.5), severe (worse than Log 
MAR 1.0) and blindness (worse than log MAR 1.3). The mean spherical equivalent was computed in 
diopters (D) as spherical power plus half the cylindrical power and recorded as the mean value of the left 
and right eye. Intraocular pressure was measured with I-care tonometer (model TA01i; Helsinki, Finland) 
on both eyes. Mydriasis was obtained by application of one drop of Tropicamide 0.5 % (Chauvin Phar-
maceuticals Ltd. Kingston upon Thames, Surrey, England) on both eyes. Retinal photography was per-
formed with a Visucam 500 (Carl Zeiss Meditec (CZM)) digital retinal camera 10-45 minutes after the 
application of Tropicamide. Five field’s 45-degree colour retinal photographs with resolution 2196x1958 
pixels were taken using the camera pre-set internal fixation. A sixth image, 30 degrees (resolution 
1620x1444 pixels) was taken centred on the macula using the “small pupil” setting. Optical coherence 
tomography (OCT) of both eyes was performed using Cirrus HD-OCT model 4000 (CZM). The standard 
512 x 128 macular cube and optic disc cube scan protocol were used and performed according to the 









Table 1: Ocular Examinations: The Tromsø Eye Study 2015-16. 
Examination type/Method/Tool Manufacturer/Specifications 
Visual acuity and Auto-refraction Nidek ARK 560a autorefractor a 
Tonometry I-care Tonometer b 
Retinal photography 
 
Visucam 500 c  
45o field fundus 
30o field optic and macular area 
Mydriasis One drop of tropicamide 0.5% d 
Optical Coherence Tomography (OCT) Cirrus HD-OCT Model 4000 e 
 
a Nidek 20 Co., LTD 
bModel TA01i, Helsinki, Finland 
c Carl Zeiss Meditec (CZM), Jena, Germany 
d Chauvin Pharmaceutical LTD, Kingston upon Thames, Surrey, England 
e Carl Zeiss Meditec (CZM), Jena, Germany 
Retinal photography and OCT scans were performed by trained technicians. Images and OCT-scans were 
stored using Forum software (CZM). Grading of retinal images was done using high quality 24” LCD 
monitors (Eizo ColorEdge CG241W/CG242W). All the valid retinal images were assessed for the pres-
ence of MRNF by a certified Ophthalmologist. The detection of the condition from the retinal photographs 
was based on its normal funduscopic appearance (see Figure 3). Eye conditions such as glaucoma and 
retinal detachment were self-reported. Branch retinal vein occlusion (BRVO), central retinal vein occlu-
sion CRVO), and arterial occlusion were diagnosed based on fundus image grading. All fundus images 
were graded for retinopathy based on ‘The International Clinical Diabetic Retinopathy and Diabetic Mac-
ular Oedema Disease Severity Scales’ (Wilkinson et al., 2003). 
2.1.4 Assessment and definitions of Systemic conditions and risk factors  
Systemic diseases assessed include self-reported heart attack, angina pectoris, atrial fibrillation, cerebral 
stroke, and heart failure. Cardiovascular risk factors (CVRFs) assessed were defined as follows: Smoking 
was dichotomized into non-smokers (never smokers) and smokers (former smokers and current smokers). 




mmHg or more in the second and third standardized measurement or mean diastolic blood pressure of 90 
mmHg or more in the second and third standardized measurement. Diabetes diagnosis applied to individ-
uals with self-reported diabetes, taking anti-diabetic medications or glycosylated haemoglobin (HbA1c) 
level of more than 48mmol/mol (6.5%). Obesity was defined as a body mass index (BMI) of 30 kg/m2 or 
more. Dyslipidemia diagnosis applied to individuals taking lipid-lowering drugs or a low-density lipopro-
tein-to-high density lipoprotein ratio of 3.5 or more. 
2.1.5 Ethics 
The Tromsø Study and The Tromsø Eye Study were approved by the Regional Committee for Medical 
and Health Research Ethics and the Data Inspectorate. In line with the tenets of the Helsinki Declaration 
for research involving humans, all participants gave written informed consent. This present study was also 
approved by “Norwegian centre for research data” no 660960, and regional ethics committee no 68904. 
2.1.6 Statistical Analysis 
All data were checked for completeness and accuracy, and missing and duplicate values were addressed. 
This study utilized the Predictive Analytics Software Statistics version 26 (SPSS, Inc, Chicago, IL) and 
Stata (Version 16.0, Stata Corp., College Station, TX) for all statistical analyses. Independent t-test was 
used to compare means for classical ocular features and systemic parameters. The Pearson Chi-square test 
or Fisher's exact test was used for comparing proportions. P-value <0.05 was considered significant. The 
results of prevalence were presented as relative numbers in per cent and weighted to the local Tromsø 
population, Europe standard population, and the WHO standard population.  
2.1.7 Logistic regression model building 
Ocular and systemic associations with MRNF were analyzed using multivariable logistic regression model 
(Odd Ratio, Confidence interval, and P-values). Variables with p<0.25 in the univariable analyses com-
bined with clinically relevant variables (stroke, age, and sex) were included in a multivariable logistic 
model. This was followed by several multivariable logistic regression models, eliminating the variable 
with the highest P-value per time. The log-likelihood ratio test was used to identify if the reduced model 
fits as well as or significantly better than the preceding model. In each succeeding model, the coefficients 




coefficients (Δβ) was more than 20%, the excluded predictors were adjudged to have provided important 
adjustment of the effect of remaining variables. Such variables were therefore added back to the model. 
This process of elimination and addition of variables and model fitting and refitting continued until all 
variables excluded were both clinically and statistically insignificant. The final model included only var-





Readable fundus photographs of at least one eye were available in 7396 (88.0%) of 8346 participants of 
the Tromsø eye study 2 (TES2). Table 2 shows characteristics of the study population stratified by sex. 
The study cohort included 3979 (55.8%) females and 3417 (46.2%) males. The mean age in the whole 
study cohort was 62.9 ± 10.4 years with 62.8 ± 10.4 and 63.1 ± 10.4 years in females and males respec-
tively (Table 2). In total, MRNF lesions were present in 91 eyes of 81 (1.1%) subjects, out of which 33 
(40.7%) were females and 48 (59.3%) were males. Unweighted prevalence of MRNF was 1.1%. The 
prevalence weighted to the Tromsø population, the European standard population and the WHO standard 





Table 2: Characteristics of Study Participants. N =7396. Tromsø Eye Study 2015/2016. 
     Variable   All subjects  Males  Females P-value 
    Sex                                    7396                      3,417 (46.2) 3,979 (53.8)  
Age (years)  62.9 ± 10.4  63.1 ± 10.4 62.8 ± 10.4 0.185* 
BMI (kg/m2)  27.3 ± 4.4  27.8 ± 3.9 26.9 ± 4.7     < 0.001** 
Obesity n, (%)  1,753 (23.8)  842 (24.7) 911 (23.0) 0.091* 
LDL (mmol/l)  3.6 ± 1.0  3.5 ± 1.0 3.7 ± 1.0       < 0.001** 
HDL (mmol/l)  1.6 ± 0.5  1.4 ± 0.4 1.8 ± 0.5       < 0.001** 
Triglyceride (mmol/l) 1.5 ± 0.9  1.6 ± 0.9 1.4 ± 0.7       < 0.001** 
Total Chol (mmol/l) 5.5 ± 1.1  5.3 ± 1.1 5.7 ± 1.1       < 0.001** 
Blood glucose (mmol/l) 5.5 ± 1.4  5.7 ± 1.5 5.4 ± 1.3       < 0.001** 
HbA1c (%)  5.8 ± 0.6  5.8 ± 0.6 5.7 ± 0.5       < 0.001** 
Mean SP (mmHg) 133.2 ± 20.1  134.6 ± 18.3 132.1 ± 21.5 < 0.001** 
Mean DP(mmHg)  75.5 ± 9.9  77.9 ± 9.6 73.4 ± 9.6     < 0.001** 
Oxygen saturation 97.8 ± 1.3  97. 6 ± 1.4 98.0 ± 1.3     < 0.001** 
Serum CRP (mg/l) 2.2 ± 6.1  2.3 ± 6.8 2.1 ± 5.3 0.160** 
Smoking n, (%)  4481 (61.2)  2120 (62.6) 2361 (60.0) 0.024* 
Hypertension n, (%) 3787 (51.7)  1873 (55.4) 1914 (48.6)  < 0.001* 
Diabetes; n, (%)  524 (7.3)  281 (8.5) 243 (6.4) 0.001* 
Heart attack; n, (%) 358 (5.0)  263 (8.0) 94 (2.5)        < 0.001* 
Heart failure; n, (%) 195 (2.7)  141 (4.3) 54 (1.4)        < 0.001* 
Atrial Fibrillation; n, (%) 558 (7.9)  344 (10.4) 214 (5.7)      < 0.001* 
Angina pectoris; n, (%) 229 (3.2)  143 (4.3) 86 (2.3)        < 0.001* 
Stroke; n, (%)  242 (3.4)  147 (4.4) 94 (2.5)        < 0.001* 
Migraine; n, (%)  1,024 (14.4)  246 (7.4) 778 (20.5)    < 0.001* 
Dyslipidemia; n, (%) 1,161 (15.7)  746 (21.9) 415 (10.5)    < 0.001* 
Ocular Parameters 
Mean IOP (mmHg) 13.9 ± 3.4  13.9 ± 3.5 13.8 ± 3.4 0.929** 
Mean SE (diopters) -0.007 ± 2.2  0.005 ± 2.1 -0.018 ± 2.3 0.658** 
Glaucoma; n, (%)  201 (2.7)  83 (2.4) 118 (2.9) 0.157* 
Retinopathy; n, (%) 924 (13.3)  461 (14.5) 463 (12.3) 0.008* 
BRVO; n, (%)  75 (1.0)  39 (1.1) 36 (1.0) 0.311* 
CRVO; n, (%)  12 (0.2)  6 (0.2)  6 (0.2)  0.791* 
Arterial occlusion; n, (%) 14 (0.2)  6 (0.2)  8 (0.2)  0.802* 
Retinal detachment n, (%)119 (1.6)  60 (1.8)        59 (1.5) 0.354* 
  
*Chi-Square test, **T-test 
Values are mean ± SD for continuous variables and n (%) for proportions. SE= Spherical equiv-
alent. IOP = Intraocular pressure. BRVO = Branch Retinal Vein Occlusion. CRVO = Central 
Retinal Vein Occlusion. SP = Systolic Pressure. DP = Diastolic Pressure. Boldface indicates sig-




Table 3 below illustrates the classification of visual impairment, while Table 4 shows the age and 
gender-specific prevalence of MRNF in the study sample. 
Table 3: Grouping of Visual Acuity based on the International Classification of Visual Impair-
ment. N =7330 
Categories Best eye VA Worst eye VA 
Severe VI 6 (0.1) 75 (1.0) 
Moderate VI  6 (0.1) 79 (1.1) 
Mild VI 226 (3.1) 824 (11.2) 
No VI 7090 (96.7) 6352 (86.7) 
VI = Visual Impairment. VA = Visual Acuity. Values are n (%) 
 
Table 4: Prevalence of MRNF by age and gender. The Tromsø Eye Study 2015/2016. 
 Male Female 
Decade of Age (years) n MRNF n MRNF 
40-49 482 4 (0.8) 570 4 (0.7)    
50-59 539 10 (1.9) 728 7 (1.0) 
60-69 1427 19 (1.3) 1580 11 (0.7) 
70-79 821 15 (1.8) 949 9 (0.9) 
80+ 148 0 (0.0) 152 2 (1.3) 
Total 3417 48 (1.4) 3979 33 (0.8) 
Values are n (%) 
Among those manifesting MRNF, 10 subjects (12.3%) had bilateral lesions while 71 (87.7%) had 
unilateral lesions. Unilateral MRNF was present in 32 right eyes and 39 left eyes. Compared with 
the study participants without MRNF, subjects with MRNF did not vary significantly in age (63.4 
± 9.7 years versus 62.9 ± 10.4 years; P = 0.698). However, in the univariable logistic regression 
analysis, this study found a significant association between MRNF and sex (P = 0.019, Odds ratio 





Table 5: Univariable Regression Analysis: Associations of Demographic, Anthropometric, Ocular, 
and Systemic Parameters with the Presence of MRNF. The Tromsø Eye Study 2015/2016. 
Variables                                   Beta Coefficient Odd Ratio 95% CI      P-Value 
Age (years) 0.004 1.004 0.983 – 1.026  0.698 
Sex, males 0.533 1.704 1.091 – 2.66  0.019 
BMI (kg/m2)                                      - 0.024 0.976 0.927 – 1.028  0.360 
Obesity (BMI>=30kg/m2)                  - 0.320 0.726 0.414 – 1.276  0.266 
LDL (mmol/l)                                     - 0.039 0.961 0.773 – 1.197  0.725 
HDL (mmol/l)                                    - 0.310 0.733 0.458 – 1.173  0.196 
Triglyceride (mmol/l) 0.027 1.027 0.801 – 1.316  0.834 
Total Cholesterol (mmol/l)                 - 0.090 0.914 0.748 – 1.118  0.381 
Blood glucose (mmol/l)                      - 0.111 0.895  0.725 – 1.104  0.298 
HbA1c (%)                                         - 0.470 0.625 0.368 – 1.062  0.082 
Mean Systolic pressure (mmHg) 0.004 1.004 0.993 – 1.014  0.519 
Mean diastolic pressure (mmHg) 0.014 1.014 0.992 – 1.037  0.205 
Oxygen saturation 0.037 1.038 0.878 – 1.227  0.661 
Serum CRP (mg/l)                              - 0.032 0.969 0.889 – 1.055  0.463 
Hypertension 0.235 1.265 0.810 – 1.975  0.301 
Diabetes                                              - 0.165 0.848 0.341 – 2.107  0.722 
Smoking 0.002 1.002 0.637 – 1.574  0.995 
Heart attack                                        - 0.149 0.862 0.483 – 1.538  0.615 
Heart failure                                       - 0.085 0.918 0.224 – 3.765  0.906 
Atrial Fibrillation                               - 0.769 0.463 0.146 – 1.474  0.193 
Angina pectoris                                  - 0.264 0.768 0.188 – 3.145  0.714 
Stroke 0.205 1.228 0.739 – 2.038  0.428 
Migraine                                             - 0.057 0.945 0.498 – 1.792  0.863 
Dyslipidemia 0.277 1.319 0.761 – 2.228  0.324 
Ocular Parameters      
Mean IOP (mmHg) 0.000 1.00 0.926 – 1.082  0.998 
Best eye visual acuity 0.312 1.367 0.363 – 5.147  0.644 
Worst eye visual acuity 0.214 1.239 0.712 – 2.158  0.449 
Mean Sph eqivalent (diopters)           - 0.064 0.938  0.855 –1.028  0.172 
Glaucoma 0.626 1.870 0.678 – 5.161  0.227 
Retinopathy 0.378 1.459 0.698 – 3.049  0.315 
Retinal detachment                             - 0.278 0.757 0.104 – 5.486  0.783 




3.1 Ocular Associations 
Compared with study participants without MRNF, subjects with MRNF did not vary significantly 
in mean spherical equivalent (P = 0.172, Odds ratio (OR): 0.938 ; 95% CI:  0.855 –1.028 ), mean 
intraocular pressure (P = 0.998, Odds ratio (OR): 1.00; 95% CI: 0.926 – 1.082), presence of glau-
coma (P = 0.227, Odds ratio (OR): 1.870; 95% CI: 0.678 – 5.161), retinopathy (P = 0.315, Odds 
ratio (OR): 1.459; 95% CI: 0.698 – 3.049) and visual acuity (Table 5). There were no cases of 
MRNF in subjects with BRVO, CRVO and arterial occlusion, hence, they were excluded from the 
analysis (Table 5). 
3.2 Cardiovascular Associations 
The present study found no significant association between the presence of MRNF and diabetes 
(P = 0.722, Odds ratio (OR): 0.848; 95% CI: 0.341 – 2.107), high blood pressure (P = 0.301, Odds 
ratio (OR): 1.265; 95% CI: 0.810 – 1.975), obesity (P = 0.266, Odds ratio (OR): 0.726; 95% CI: 
0.414 – 1.276) and smoking (P = 0.995, Odds ratio (OR): 1.002; 95% CI: 0.637 – 1.574). More so, 
our study did not report a significant association between the presence of MRNF and other sys-
temic conditions such as atrial fibrillation, angina pectoris, heart attack, heart failure, dyslipidemia 
or stroke (Table 5). Similarly, lipid profile assessment (Total cholesterol, LDL, HDL and triglyc-
erides), oxygen saturation, serum glucose, serum CRP, HbA1c, body mass index and migraine did 
not show a significant difference between subjects manifesting MRNF and the rest of the cohort 
(Tables 5). 
3.3 Multivariable Analyses 
Variables with P-value < 0.25 in the univariable analysis, together with history of stroke, age, and 
sex were included in a multivariable logistic regression model (Table 6). The inclusion of clinically 
relevant variables in our multivariable logistic regression models even when they were not statis-
tically significant is a reflection of the “part experience and common sense” nature of model build-
ing strategy. In this model, only sex (male) and HbA1c were significantly associated with the 




Table 6: Multivariable Logistic Regression Analysis (Dependent Variable: Presence of Myelinated 
Retinal Nerve Fibers, MRNF) including Age, Sex, stroke and the parameters that showed a P-value 
<0.25 in the Univariable Analysis. The Tromsø Eye Study 2015/2016. 
Variables Beta Coefficient Odds Ratio 95% CI P-Value 
Age (years) 0.015 1.015 0.991 – 1.040 0.233 
Sex (male) 0.520 1.682 1.006 – 2.281 0.047 
HBA1C %                    - 0.700 0.496 0.268 – 0.920 0.026 
HDL (mmol/l)              - 0.299 0.742 0.432 – 1.273 0.278 
Diastolic BP (mmHg) 0.005 1.005 0.981 – 1.029 0.712 
Stroke 0.137 1.146 0.635 – 2.069 0.650 
Atrial Fibrillation         - 0.830 0.436 0.135 – 1.409 0.165 
Mean SE (Diopters)     - 0.071 0.932 0.844 – 1. 028 0.158 
Glaucoma 0.861 2.365 0.832 – 6.724 0.106 
Boldface indicates significance at P<0.05, CI = Confidence Interval, BP = Blood Pressure, SE = 
Spherical equivalent.  
A final logistic regression model was formed that included age and variables that were statistically 
significant at less than 5% (Table 7). In this model, male sex (P = 0.012, Odds ratio (OR): 1.785; 
95% CI: 1.138 – 2.799) was associated with increased odds for MRNF, while glycosylated hemo-
globin (P = 0.046, Odds ratio (OR): 0.559; 95% CI: 0.316 – 0.989) was associated with decreased 
odds for developing MRNF.   
Table 7: Multivariable Logistic Regression Analysis (Dependent Variable: Presence of Myelinated 
Retinal Nerve Fibers, MRNF) including age and variables significant at less than 5%. The Tromsø 
Eye Study 2015/2016. 
Variables Beta Coefficient Odds Ratio 95% CI P- Value 
Age (years) 0.012 1.012 0.990 – 1.035 0.286 
Sex 0.579 1.785 1.138– 2.799 0.012 
HBA1C %            - 0.581 0.559 0.316 – 0.989 0.046 




4 Discussion  
To our knowledge, there are few previous reports on the population-based prevalence and associ-
ations of MRNF. The present study provides this data for a population sample of subjects who 
were between the ages of 40 and 84 years. It is the first population-based study in the Nordic region 
and the second in Europe after the Gutenberg Health Study that provides data on the prevalence, 
as well as ocular and systemic associations of MRNF in Caucasians.   
The results of this study show a higher prevalence of MRNF in individuals with European back-
ground than previously reported in the Gutenberg Health Study (Elbaz et al., 2016). More so, the 
present study found a higher prevalence of MRNF than previously reported in other parts of the 
world. The Beijing Eye Study found a prevalence of 0.7% in 4,378 participants in China (You et 
al., 2007).  Kodama and colleagues reported a prevalence of 0.6% among Japanese subjects 
(Kodama et al., 1990). Straatsma documented a prevalence of 0.98% in 3,968 subjects in the 
United States (Straatsma et al., 1981). The Central India Eye and Medical Study reported a prev-
alence of approximately 1.0% in 4,485 adult Indians (Nangia et al., 2014), and Cinar and col-
leagues documented a prevalence of 0.34% in 6,250 subjects in Turkey (Cinar, Zengin, & 
Kucukerdonmez, 2015). The prevalence of MRNF within the Tromsø Eye Study was 1.1%. The 
prevalence weighted to the Tromsø population, the European standard population and the WHO 
standard population was calculated as 1.08%, 1.05%, and 1.04% respectively. While we could not 
establish a plausible explanation for our study’s higher MRNF prevalence, however, we speculate 
that it could be due to the number of images taken during fundus photography. Our study utilized 
five different images per eye for the assessment of the presence of MRNF, although it is not clear 
the number of images the above studies utilized in their assessment. 
In agreement with the Gutenberg Health Study (Elbaz et al., 2016), the Central India Eye and 
Medical Study (Nangia et al., 2014), and the Beijing Eye Study (You et al., 2007), the present 
study did not report a significant association between MRNF and age. However, myelination of 
retinal nerve fibre was least common in the fourth and eighth decades of life, followed by the sixth 
decade, and distributed evenly throughout the other decades (Figure 4). As in the Gutenberg Health 




this eye-difference was not statistically significant. There is conflicting evidence in the literature 
regarding the association between sex and MRNF. The Gutenberg Health Study (Elbaz et al., 2016) 
and Straatsma (Straatsma et al., 1981) reported no statistically significant gender difference in 
MRNF prevalence, while Kodama and associates reported female predominance (Kodama et al., 
1990). On the contrary, the present study, as well as the Central India Eye and Medical Study 
(Nangia et al., 2014), reported a higher prevalence of MRNF lesions in males. We found MRNF 
in 1.4% of males and 0.8% of females in our study sample. This gender difference was statistically 
significant, although the reason for this finding is unclear.   
In the subjects within the Tromsø Eye study, the prevalence of MRNF was not significantly asso-
ciated with ocular parameters such as refractive error, best-corrected visual acuity, and intraocular 
pressure. In addition, our study did not report a significant association between MRNF and other 
ocular conditions such as retinopathy, retinal detachment, and glaucoma. The finding of this study 
is in agreement with the results of previous population-based studies (Cinar et al., 2015; Elbaz et 
al., 2016; Nangia et al., 2014; You et al., 2007).   
Several oculo-visual parameters have been reported in conjunction with MRNF mostly by case 
reports and series. Extensive unilateral as well as bilateral (rarely) cases of MRNF has been asso-
ciated with mild hyperopia, emmetropia or myopia in the affected eye (Straatsma et al., 1979). Lee 
and associate reported an association between the presence of MRNF and anisometropic amblyo-
pia (J. C. Lee & Salchow, 2008). However, they also noted that the association was more of a 
coincidence than causally related because, their patient followed a course of treatment peculiar to 
anisometropic amblyopia rather than amblyopia associated with MRNF. More so, Osauguona and 
associate (Osaguona & Uhumwangho, 2014), Straatsma, (Straatsma et al., 1979) and Tarabishy 
(Tarabishy et al., 2007) have reported on a syndrome of anisometropic myopia, amblyopia, stra-
bismus and homolateral extensive MRNF. In addition, ocular abnormalities such as coloboma, 
keratoconus, and polycoria have been reported concurrently with MRNF (Straatsma et al., 1979). 
Nonetheless, these findings are neither shared by the present study nor by other previous popula-




above may have been potentially impacted by coexisting organic or structural pathology. For in-
stance, Tarabishy and associates (Tarabishy et al., 2007) also reported the presence of optic nerve 
dysplasia in some of the patients examined. 
The effect of MRNF on visual function is highly contestable, and, it is influenced by the location, 
area of the lesion, as well as by coexisting visual pathology. In some cases, visual function may 
be affected if the MRNF lesions are widespread or if there is a macula involvement. Interestingly, 
several cases of retinal nerve fibre myelination neither show visual deficits nor significant refrac-
tive anomalies. In MRNF, visual function and prognosis rely on the severity of ocular complica-
tions or associated conditions. The query as to whether retinal myelination causes visual deficits or 
vice versa remains debatable. Ruttum and poll, in their study, suggested that anisometropia could 
be a more powerful influence on the relative visual acuity of each of the eyes than the presence of 
MRNF (Ruttum & Poll, 2006).  
4.1 Systemic parameters and MRNF  
The present study is the first to report a significant association between MRNF and glycosylated 
haemoglobin (HbA1c). This unexpected finding was observed in the multivariable logistic models. 
Although previous studies have reported associations of HbA1c with ocular signs such as macular 
oedema (Chou, Wu, Kuo, Lai, & Kuo, 2009) and average thickness of retinal nerve fibre layer (Shi 
et al., 2018), however, there is no known pathophysiological connection between the absence of 
MRNF and HbA1c. Thus, the significant association between MRNF and HbA1c reported in our 
study could be a chance finding as we could not establish a plausible explanation for it.   
Conversely, our study did not find a significant association between MRNF and cardiovascular 
risk factors such as systolic BP, diastolic BP, blood glucose level, serum lipids, diabetes, smoking, 
and hypertension. Similarly, we did not establish a significant relationship between MRNF and 
other systemic conditions such as atrial fibrillation, dyslipidemia, heart attack, and heart failure. 




4.2 Myelinated Retinal Nerve Fibre and Stroke  
The Gutenberg Health Study reported a positive association between MRNF and a history of stroke 
(Elbaz et al., 2016). This finding is neither shared by our study nor by other previous studies. The 
reason for the disparity in findings is not entirely clear. However, there are two things to deduce 
from the report of the Gutenberg Health Study. First, the statistical power of the result was low 
due to the low prevalence of MRNF reported in the study. Second, the confidence interval around 
the effect estimate was wide (2.86, 16.09) which might have impacted the precision of the result 
thus, reducing the confidence on the reliability of the finding. 
Indeed, stroke patients demonstrate microvascular changes in the retina. For example, previous 
studies have reported on the stroke-induced retinal damage and microvascular changes such as 
increased retinal vascular tortuosity, reduced dimension of retinal fraction, retinal haemorrhage, 
arteriolar narrowing and increased venular diameter (Kumar, 2017). Several studies have also re-
ported associations between stroke and certain retinal signs such as retinal vein occlusion, age-
related macular degeneration, diabetic and hypertensive ocular signs (Baker, Hand, Wang, & 
Wong, 2008). Besides, a study conducted with animal model showed that cerebral ischemia re-
sulted in retinal and optic nerve degeneration in rats (Stevens, Fortin, & Pappas, 2002). However, 
as this present study did not report a statistically significant association between MRNF and history 
of cerebral stroke, we, therefore, could not comment on any potential clinical relevance of MRNF 
in patients presenting with stroke.  
Retinal imaging has been widely considered to be a very powerful tool in understanding and pre-
dicting stroke (Kumar, 2017). And to understand the impact of systemic parameters on vision, it 
is important to recall that the retinal and cerebral small vessels share similar embryological origins, 
anatomical features and pathophysiological properties (London et al., 2013). Hence, it would be 
logical to observe a more in-depth study of the actions of the myelin-producing cells as regards 
systemic diseases in general, as well as cardiovascular and cerebrovascular conditions in particu-
lar. This may be useful in order to fully comprehend the clinical implications of random detection 




Associations between acute retinal events and acute systemic parameters have both clinical and 
epidemiological implications with regards to optimizing clinical care to reduce the ample morbid-
ity and mortality of stroke. Vision loss precipitated by cerebral infarction often results in reduced 
quality of life and can lead to loss of independence and depression (Hepworth & Rowe, 2016). 
Due to the disparity between our study and the report of the Gutenberg Health Study regarding the 
association of MRNF with history of stroke, there is need for further studies to confirm the role of 
MRNF in stroke patients. These further studies are recommended in diverse populations and with 
bigger sample size. This is crucial before considering whether or not to include MRNF in predic-
tion models containing stroke risk factors.  
4.3 Strengths and limitations of the study  
The strengths of this present study include the population-based design and sizeable sample size, 
relatively high response rate and high percentage of gradable retinal images. Furthermore, a de-
tailed ophthalmic examination was undertaken allowing adjustment for important covariates in the 
analyses. However, there are limitations to this study. First, as this was a cross-sectional study, we 
could not establish any cause-and-effect relationship. Second, there is a legitimate concern for 
selection bias as some of the study participants were selected through predetermination. Finally, 
as much as we are inclined to believe that our study includes a representative survey of the general 
Norwegian population, however, the generalizability of our data beyond the Tromsø municipality 
and the examined age group is not certain. 
5 Conclusion  
In conclusion, the present study provides prevalence estimates of MRNF that are different from 
previous epidemiological studies in Caucasian and other populations. To the best of our 
knowledge, it is the first study to provide prevalence estimates of MRNF and its associations in 
the Nordic population. Importantly, this is also the first population-based study to report an asso-
ciation between MRNF and HbA1c, although this may be a chance finding and must be explored 




on retinal abnormalities associated with systemic diseases, and some on MRNF, the general per-
ception that MRNF is without serious clinical implication is probably true, although this must be 
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